Hood Laboratories downclassification petition for valved endolymphatic shunt denied by FDA.
This article was originally published in The Gray Sheet
Executive Summary
HOOD LABS' VALVED ENDOLYMPHATIC SHUNT TUBE DENIED CLASS II STATUS by FDA in a Dec. 9 Federal Register notice. Denying a reclassification petition filed by E. Benson Hood Laboratories in May 1990, FDA says the firm failed to "present sufficient new scientific information" to address the safety and efficacy concerns related to: the range of physiological pressures within the endolymphatic sac; the mode of action of the endolymphatic shunt tube with valve; and the flow characteristics attributable to effective functioning of the valve.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.